| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Tribehenin does not target a specific protein or enzyme for pharmacological intervention. Its utility is as a pharmaceutical excipient and cosmetic ingredient. In pharmaceutical formulations, it is mainly used as a lubricant in the preparation of oral tablets and capsules. In cosmetics, it is used as a skin conditioner, emollient, and viscosity-increasing agent in emulsions.
|
|---|---|
| ln Vitro |
The in vitro activity of Tribehenin is its function as a pharmaceutical excipient and cosmetic ingredient. The compound is a soft, amorphous triglyceride of behenic acid that reduces crystallinity and rigidity of waxes. It is used as a lubricant in tablet and capsule formulations and as a skin conditioner and emollient in cosmetics.
|
| ln Vivo |
No significant in vivo activity has been reported for Tribehenin as a therapeutic agent. The compound is primarily utilized as a pharmaceutical excipient and cosmetic ingredient rather than a pharmacologically active compound.
|
| Enzyme Assay |
In vitro assays for Tribehenin are not typically performed in the context of enzyme or receptor binding. The compound is used in pharmaceutical formulation studies to evaluate its properties as a lubricant and excipient.
|
| Cell Assay |
For in vitro cellular experiments, Tribehenin is not typically used in cell-based assays. The compound is primarily used as a pharmaceutical excipient in tablet and capsule formulations.
|
| Animal Protocol |
In vivo animal experiments with Tribehenin are not commonly performed as a therapeutic intervention. The compound is primarily used as a pharmaceutical excipient in drug formulations.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Tribehenin have not been characterized for therapeutic use. As a pharmaceutical excipient, it is not intended to be absorbed systemically. The compound has a molecular weight of 1059.8 g/mol and should be stored at room temperature in a cool, dark place below 15°C.
|
| Toxicity/Toxicokinetics |
Toxicity Summary
This product is safe within its current usage and concentration range. Information on ingredients, concentrations, and usage can be found at: https://cir-reports.cir-safety.org The compound is intended for pharmaceutical and cosmetic use as an excipient and ingredient. Standard laboratory safety precautions should be observed when handling this chemical reagent. |
| Additional Infomation |
Tribehenin is a triglyceride of behenic acid used as a pharmaceutical excipient (lubricant in tablets and capsules) and cosmetic ingredient (skin conditioner, emollient). The compound has no clinical or therapeutic applications as an active pharmaceutical ingredient.
|
| Molecular Formula |
C69H134O6
|
|---|---|
| Molecular Weight |
1059.80
|
| Exact Mass |
1059.018
|
| CAS # |
18641-57-1
|
| PubChem CID |
62726
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
911.8±32.0 °C at 760 mmHg
|
| Melting Point |
82.5 °C
|
| Flash Point |
321.6±25.2 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.467
|
| LogP |
31.64
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
68
|
| Heavy Atom Count |
75
|
| Complexity |
1070
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O)C([H])(C([H])([H])OC(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O)C([H])([H])OC(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O
|
| InChi Key |
DMBUODUULYCPAK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C69H134O6/c1-4-7-10-13-16-19-22-25-28-31-34-37-40-43-46-49-52-55-58-61-67(70)73-64-66(75-69(72)63-60-57-54-51-48-45-42-39-36-33-30-27-24-21-18-15-12-9-6-3)65-74-68(71)62-59-56-53-50-47-44-41-38-35-32-29-26-23-20-17-14-11-8-5-2/h66H,4-65H2,1-3H3
|
| Chemical Name |
2,3-di(docosanoyloxy)propyl docosanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9436 mL | 4.7179 mL | 9.4357 mL | |
| 5 mM | 0.1887 mL | 0.9436 mL | 1.8871 mL | |
| 10 mM | 0.0944 mL | 0.4718 mL | 0.9436 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
